# Nuvita İlaç, Manufacturing Arm of Orzax, Climbs the Ranks in Turkey R&D 500

> Nuvita İlaç, the strategic manufacturing operations base for Orzax, climbed 17 spots to 231st place among Turkey's highest R&D-spending companies in the Turkey R&D 500 Survey. Increasing its R&D expenditure by 53.8% to TL 84.8 million, the company also rose to 41st place nationwide with 49 active R&D projects.

Published: 2026-09-10T11:02:00+00:00
Language: en
Categories: [Pharmaceutical Industry](https://chemexworld.com/en/categories/sectors/pharmaceutical-industry-1.md)

Canonical URL:
https://chemexworld.com/en/news/nuvita-ilac-manufacturing-arm-of-orzax-climbs-the-ranks-in-turkey-rd-500

## Content

Operating as the manufacturing center of healthcare brand Orzax, Nuvita İlaç achieved measurable gains in the 2025 edition of the Turkey R&D 500 Survey, conducted annually by the business publication Turkishtime. Compiled from public disclosures, Ministry-accredited R&D centers, and leading exporter metrics, the survey benchmarks corporate innovation capital across the country.

### 53.8% Growth in R&D Expenditure to TL 84.8 Million

Key operational metrics regarding Nuvita İlaç’s research and project footprint include:

- **Expenditure Rankings:** Advanced 17 positions year-on-year from 248th to **231st place**, securing its position among Turkey’s top 250 investing enterprises.
- **Investment Volume:** Annual R&D expenditures grew by **53.8%**, reaching **TL 84.8 million**.
- **Project Volume Expansion:** The number of active research projects increased from 38 to 49—a 28.9% rise. This elevated the company 24 places from 65th to **41st position nationwide**, entering the top 50 corporate leaders in total project volume.

![](https://chemexworld.com/storage/uploads/orzaxin_uretim_gucu_nuvita_ilac_ar_ge_500de_yukselisini_surdurdu.jpg)

### Statement from R&D Manager Akif Emre Kavak

**Akif Emre Kavak, R&D Manager at Nuvita İlaç**, stated:

> We regard R&D as an essential pillar of our sustainable growth and high-value manufacturing vision. By combining scientific knowledge with our production competencies, our projects contribute both to our industry's advancement and the national R&D ecosystem. Through innovative programs run at our R&D center, we introduce new product and manufacturing solutions while deepening capabilities in strategic raw materials. Looking ahead, we will continue investing in science and innovation to deliver high-value solutions that support human health.